// App-Quantinova.ai

147 : Predictive biomarkers of sensitivity to androgen receptor signaling (ARS) and taxane-based chemotherapy in circulating tumor cells (CTCs) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Howard I. Scher

Principal Investigators

  • Jessica Louw

  • Adam Jendrisak

  • Mark Landers

  • Dana E. Rathkopf

  • Zaina Arslan

  • Nicole A. Schreiber

  • David Lu

  • Rachel Krupa

  • Dena Marrinucci

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NYEpic Sciences, Inc., San Diego, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Cluster of differentiation 45

Drug/Treatment

  • Androgen Tear

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved